---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-038730"
form_type: "8-K"
ticker: "CNTN"
cik: "0001861657"
company_name: "Canton Strategic Holdings, Inc."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:54:11.426722+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tharimmune signs nonbinding LOI to merge with Intract Pharma; 49% stake for Intract shareholders

## Summary
- Tharimmune and Intract Pharma entered nonbinding LOI; Tharimmune to acquire Intract for restricted stock.
- Intract shareholders will own 49% of combined entity; merger expected to close in Q1 2025.
- Combined company will leverage Intract's Soteria and Phloral oral delivery platforms for biologics.
- Existing license for oral anti-TNF antibody (INT-023/TH023) from Intract remains unaffected.
- Transaction aims to expand Tharimmune's pipeline in inflammation and immunology.

## SEC filing metadata
- accession: 0001493152-24-038730
- form_type: 8-K
- ticker: CNTN
- cik: 0001861657
- company_name: Canton Strategic Holdings, Inc.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861657/000149315224038730/0001493152-24-038730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861657/000149315224038730/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-038730
- JSON: https://secwatch.observer/filing/0001493152-24-038730.json
- Plain text: https://secwatch.observer/filing/0001493152-24-038730.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.